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Hirschsprung disease (HSCR) is a common malformation of neural-crest–derived enteric neurons that is frequently
associated with other congenital abnormalities. The SMADIP1 gene recently has been recognized as disease causing
in some patients with 2q22 chromosomal rearrangement, resulting in syndromic HSCR with mental retardation,
with microcephaly, and with facial dysmorphism. We screened 19 patients with HSCR and mental retardation and
eventually identified large-scale SMADIP1 deletions or truncating mutations in 8 of 19 patients. These results allow
further delineation of the spectrum of malformations ascribed to SMADIP1 haploinsufficiency, which includes
frequent features such as hypospadias and agenesis of the corpus callosum. Thus, SMADIP1, which encodes a
transcriptional corepressor of Smad target genes, may play a role not only in the patterning of neural-crest–derived
cells and of CNS but also in the development of midline structures in humans.
Hirschsprung disease (HSCR [MIM 142623]), the most
common (1/5,000 live births) malformative cause of in-
testinal obstruction, has a complex inheritance and is fre-
quently associated with other congenital abnormalities
(Lyonnet et al. 2001). In particular, the combination of
severe mental retardation, postnatal microcephaly, epi-
lepsy, and facial dysmorphism has been recently recog-
nized as an independent syndrome (Mowat et al. 1998).
This syndrome has occasionally been ascribed to an in-
terstitial deletion of chromosome 2q22 (Lurie et al. 1994;
Mowat et al. 1998). Most recently, two de novo transloca-
tions—46,XX,t(2;13)(q22;q22) (Wakamatsu et al. 2001)
and 46,XY,t(2;11)(q22.2;q21) (Cacheux et al. 2001)—
allowed the identification of the gene encoding Smad-
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interacting protein 1 (SMADIP1 [MIM 605802]) as the
disease-causing gene in this syndrome.
Yet, the prevalence of SMADIP1 mutations and the
spectrum of their clinical manifestations have remained
ignored. Starting with a series of 250 nonfamilial cases
of HSCR, we screened 19 unrelated patients with mental
retardation, for possible SMADIP1 mutations. Here, we
report large-scale SMADIP1 deletions or truncating mu-
tations in ∼50% (8 of 19) of these patients. Hypospadias
and agenesis of the corpus callosum were frequently ob-
served, allowing further delineation of this syndrome
and suggesting that Smadip1 may play a role not only
in the patterning of neural-crest–derived cells and of
CNS but also in the development of midline structures
in humans.
Nineteen patients from a larger series, of 250 patients
with HSCR, were included in the series that we studied,
on the basis of the following criteria: (1) normal chro-
mosome analysis on standard examination, (2) moder-
ate-to-severe mental retardation, and (3) either facial
dysmorphism, cerebral anomaly including seizures,
microcephaly, or agenesis of the corpus callosum. All
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Figure 1 SMADIP1 deletions. A, Chromosome 2 of patient S.228 and FISH analysis of patient S.259. Left, RTBG karyotype, showing
chromosome 2 at 850-band resolution for patient S.228. Right, Metaphase of patient S.259, hybridized with probes BAC 95O9 (SMADIP1)
and PAC 164D18 (7qter) as control. B, Haplotype analysis at SMADIP1 locus in patients S.179 and S.203. The poly(CA) microsatellite markers
used (and genetic distances [in cM]) are as follows: cen-D2S122-(1.2)-D2S132-(0.5)-D2S381-(0.6)-[D2S298-(?)]-D2S151-tel. SMADIP1 lies
between D2S132 and D2S381.
patients were sporadic cases born of healthy, noncon-
sanguineous parents. Short-segment and long-segment
HSCR were found in six and four patients, respectively,
whereas the length of aganglionosis was not known in
eight patients; finally, one patient (patient S.272) with
severe constipation was included in the series, although
HSCR was not confirmed. The detailed clinical findings
regarding these 19 patients are summarized in table 1.
Patient S.179 has been described elsewhere (Tanaka et
al. 1993). Blood samples were obtained with informed
consent, and DNA was extracted according to standard
protocols.
Chromosomal analyses (RTBG [R-bands by Thymi-
dine and BrdU by use of Giemsa], 400- and/or 850-bands
resolution) were performed for all patients. FISH was
performed using BAC RPCI-11 95O9 (GenBank acces-
sion AC010130), which contains most of SMADIP1.
DNA of BAC RPCI-11 95O9 was labeled by nick trans-
lation by standard protocol, with incorporation of flu-
orescein isothiocyanate–dUTP (fig. 1). A control probe
was prepared from PAC RPCI-1 164D18 (7qter; Knight
et al. 2000), labeled with tetramethyl-rhodamine-dUTP.
Hybridization on patients’ metaphases was performed
over 48 h. After a washing, chromosomes were counter-
stained using di-amidino-phenyl-indole. Metaphases
were examined on a Leica DMRXA epifluorescent
microscope. Images were captured and processed using
the Leica QFISH software.
To detect infracytogenetic deletions of chromosome
2q22, five poly(CA) microsatellite markers flanking the
SMADIP1 locus were tested on the patients and their
parents (fig. 2; primer sequences are available from the
Genome Database). Moreover, real-time semiquantita-
tive PCR at the SMADIP1 locus was performed by hot-
start PCR in glass capillaries by use of the LightCycler
FastStart DNA Master SYBR Green I kit (Roche). The
amplification was performed using primers encoding
exon 6 of SMADIP1 (table 2). Exon 3 of the GDNF
gene on chromosome 5 was used as a control (forward,
ATGTCACTGACTTGGGTCTG; and reverse, TGCAC-
TGTAGCAGGAATGC). The PCR mixture contained
50 ng leukocyte DNA, 5 pmol each primer, and 2 ml
reaction mixture, in a final volume of 20 ml (3 mM
MgCl2). Forty cycles of amplification were performed,
each cycle consisting of 15 s denaturation at 95C, 10
s annealing at 50C, and 30 s elongation at 72C. After
amplification, a melting curve was performed (10 s at
95C, 20 s at 65C, and a slow dehybridization step at
Table 1
Clinical Findings, at the SMADIP1 Locus, in the Series of 19 Patients Studied
PHENOTYPE
STATUS OF PATIENTa
S.99 S.103 S.107 S.166 S.167 S.177 S.179 S.184 S.203 S.226 S.228 S.230 S.233 S.238 S.259 S.264 S.266 S.272 S.273
Sex M M M M M M F F F ? M F F M F M F F M
HSCRb   SS   LS  LS SS  SS SS SS SS LS  LS  
Neurological findings:
Postnatal microcephaly ?     ?      ?  ?  ? ?  
Agenesis of corpus callosum      ?    ?       ?  
Epilepsy ? ?        ?       ?  
Mental retardationc          ?         
Facial dysmorphism: ?        ?   ?      
Eye regiond     ?      
Saddle nose     ?      
Earse     ?      
Pointed chin     ?      
Heart defect                   
Hypospadiasf ?      NR NR NR   NR NR  NR  NR NR 
Renal anomalies ?                  
Pyloric stenosis ?                  
SMADIP1 mutation                   
a  p Affected;  p unaffected; ? p unknown.
b SS p short-segment HSCR; LS p long-segment HSCR.
c  p Mild-to-moderate mental retardation;  p severe mental retardation.
d Characterized by sunken eyes, downward-slanting palpebral fissures, strabismus, epicanthic fold, and thick eyebrows.
e Characterized by rotated ears with uplifted, fleshy earlobes and by thick antihelix.
f NR p not relevant.
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Figure 2 Frontal and profile views of patients presenting with either deletion (A) or mutation (B) of SMADIP1. In the frontal views, note
long face with pointed chin, bushy eyebrows, sunken eyes, strabismus, epicanthic folds, saddle nose, thick helix, and fleshy, uplifted earlobes.
In the profile views, note sunken eyes, saddle nose, thick helix, and fleshy, uplifted earlobes.
65C–95C). Analysis was performed using the Light-
Cycler software (second-derivate–maximum method).
The SMADIP1 coding sequence and flanking introns
were PCR amplified using a set of 15 primer pairs (exons
2–10; table 2) and were analyzed by silver-staining SSCP.
When an abnormal SSCP pattern was identified, ge-
nomic DNA was sequenced on both strands by the fluo-
rometric method (Big Dye Terminator Cycle Sequencing
kit; Applied Biosystems) (fig. 3).
An interstitial deletion of chromosome 2q22 was ob-
served on high-resolution karyotype in patient S.228 (fig.
1A). In addition, FISH analysis showed the presence of
a deletion encompassing the SMADIP1 locus in patient
S.259 (fig. 1A). Finally, loss of heterozygosity at the
SMADIP1 locus suggested a submicroscopic deletion in
two further patients (patients S.179 and S.203; fig. 1B).
To demonstrate further evidence of a SMADIP1 deletion
in those patients, real-time semiquantitative PCR was
performed. A significant retardation in the appearance
of the amplification product (crossing point for exon 6
of SMADIP1) was observed in patients when compared
with controls (table 3). This further strengthens the ev-
idence of SMADIP1 deletions in patients S.179 and
S.203 (fig. 1B and table 3). SMADIP1 deletions occurred
de novo in three cases, and, in patients S.203 and S.259,
results indicated that the deletion was carried by a pa-
ternal chromosome 2. In conclusion, in our series, 4 of
19 patients harbor a large-scale deletion encompassing
the SMADIP1 locus.
Nucleotide variations were identified in 4 of 19 pa-
tients (fig. 3 and table 4) and consistently involved the
large exon 8 of SMADIP1 (1,969 bp; 60% of the cod-
ing sequence). The mutations included a nonsense mu-
tation (1685TrG [L562X]), 1-bp deletions or insertion
(935delG, 1805delA, or 2453insT) that resulted in a
frameshift, and a premature translation termination (at
positions 337, 606, or 840 for the 935delG, 1805delA,
or 2453insT mutations, respectively; fig. 4). Thus, in
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Table 2
Primers and PCR Conditions Used for the SMADIP1-Coding-Sequence Screening
EXON
PRIMER
ANNEALING
TEMPERATURE
(C)
PCR
PRODUCT
(bp)Forward Reverse
2 GCGATGCCCACATTGTCG TCTCGAGCCGCGTAGTG 53 229
3 ATCTCAACAGAGTGTTTAGAG GAAGATGTGAAGATGGTAC 50 354
4 TGTGCTTGGCATGCTTAG CATGACACAGGACAAATG 50 191
5 GAGATGGACTTGGGATCC CAGAGGTCAGTGCAGTG 57a 297
6 GCTGCCATTGATTTACTG GCCAATCAAAGCAATATCG 50 348
7 TTCCTCCTGCACAAAACTG AAATGCAAATGCGAGCTCC 50 191
8:
A ATCAAGGAAATGTAACGG GTGTGTAGCCATAAGAAC 50 346
B CTGAACAGACAGGCTTAC TGACTCACTACCGGAAG 50 411
C GAGGAACAAGGAGTTAC CTCAGAAAGTACAGATGAC 50 434
D CCAACAAAGCCGGAGTT TGTTAGCCTGAGAGGAG 56b 421
E CATCACCATCTATAGCAG CTGAACACTGGGTTAGTG 50 438
F TGAGCCTCTGAACTTGAC GCCACCTCTTTTCTTCATAG 53 361
9 GTGAGCACAAAGAGAAGC GAAATGTACAGCAGGACG 50 284
10:
A CTAATCACCCTGTCATC TAATGCTCTGCAAGTAAGC 53 317
B GAAAGGGCACTTGGAAC CAGCAGTGTTTTCAAGC 50 427
NOTE.—For PCR amplification, the reaction mixture (25 ml) contained 100 ng leukocyte DNA, 20 pmol each primer, 0.1 mM dNTP, 0.75
ml MgCl2 0.1 M, and 1 U Taq DNA polymerase (Gibco). Thirty cycles of amplification were performed, each cycle consisting of 30 s denaturation
at 96C, 30 s annealing, and 30 s elongation. PCR products were heated for 10 min at 96C, loaded onto a GeneGel Excel 12.5/24 kit (Amersham
Pharmacia Biotech), and electrophoresed for 2.5 h at 5C and at 15C.
a  5% Dimethyl sulfoxide.
b  2.5% Dimethyl sulfoxide.
Figure 3 SSCP patterns in patients S.103, S.107, S.230, and S.272. Note the abnormal SSCP pattern in the patients, as compared to their
fathers (F) and mothers (M) and to controls (C).
all patients, the three carboxy-terminal zinc-finger do-
mains (C-ZFD; fig. 4) of SMADIP1 were presumably
deleted in the mutant gene products. In addition, the
935delG mutation disrupted the fourth amino-terminal
zinc-finger domain (N-ZFD; fig. 4) and the Smad-bind-
ing domain (SBD; fig. 4) of the protein. In three of four
patients, the SMADIP1 mutation was found to have
occurred de novo (parents of patient S.103 were not
available for study; data not shown).
Dysmorphic facial features were studied in the eight
patients carrying SMADIP1 deletions or mutations.
Consistent features included sunken eyes, down-slant-
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Table 3
Results of Real-Time Semiquantitative PCR of SMADIP1, with
GDNF as a Control
SOURCE
CROSSING POINT (SD)
D1a D2bSMADIP1 GDNF
Patient S.179 23.95 (.044) 21.65 (.068) 2.3 1.23
Patient S.203 22.89 (.046) 19.92 (.1) 2.97 1.9
Father of patient S.203 21.56 (.081) 20.81 (.038) .75 .3
Mother of patient S.203 21.21 (.098) 20.66 (.093) .55 .5
Patient S.228 22.85 (.062) 20.65 (.014) 2.2 1.13
Patient S.259 22.59 (.075) 20.19 (.026) 2.4 1.33
Mother of patient S.259 22.04 (.089) 20.63 (.028) 1.4 .33
Controls (n p 2) 22.41 (.075) 21.34 (.075) 1.07 …
a D1 p Difference, in crossing point, between SMADIP1 and the
control gene, GDNF.
b D2 p Difference, in D1, between tested individuals and controls.
Table 4
Patients Presenting with a SMADIP1 Anomaly
Patient (Sex)
Agenesis
of Corpus
Callosum? Cardiac Defecta Genital Anomalyb Renal Anomalyc SMADIP1 Deletion (Method[s])d SMADIP1 Mutation
S.103 (M) Yes … Hypospadias ? … 935delG
S.107 (M) Yes … Cryptorchidism VUR … 1805delA
S.179 (F) No PDA, ASD NR … Deletion (MA, RS-PCR) …
S.203 (F) Yes ASD NR ? Deletion (MA, RS-PCR) …
S.228 (M) Yes VSD Hypospadias,
cryptorchidism
? Deletion (CS, RS-PCR) …
S.230 (F) No ASD, VSD, PS NR Hydronephrosis … 2453insT
S.259 (F) Yes AC NR ? Deletion (MA, FISH, RS-PCR) …
S.272 (F) Yes … NR … … 1685TrG (L562X)
a PDA p patent ductus arteriosus; ASD p atrial septal defect; VSD p ventricular septal defect; PS p pulmonary stenosis; AC p aortic
coarctation.
b NR p not relevant.
c VUR p vesico ureteral reflux.
d MA p microsatellite analysis; RS-PCR p real-time semiquantitative PCR; CS p cytogenetic studies.
ing palpebral fissures, strabismus, thick eyebrows with
lateral flaring, saddle nose, pointed chin, thick antihe-
lix, and rotated ears with uplifted, fleshy earlobes (fig.
2); the patients’ hands were slender, with tapered fin-
gers. Interestingly, a significant proportion of patients
presented with an agenesis of the corpus callosum (six
of eight), urogenital anomalies (four of eight), or car-
diac defects (five of eight), but no correlation between
the mutant phenotype and the clinical symptoms could
be found in our series (table 4). In particular, no clear
phenotypic differences were observed between patients
with a large-scale deletion and patients with intragenic
truncating mutations. Conversely, most SMADIP1-
mutation–negative patients did not share significant
phenotypic features.
Here, we report large-scale deletions or mutations of
SMADIP1 in eight patients presenting with a syndromic
form of HSCR characterized by severe mental retarda-
tion, by dysmorphic facial features, and by midline de-
fects. SMADIP1 has been isolated in mouse embryo by
the yeast two-hybrid system in the search for Smad-
interacting proteins (Verschueren et al. 1999). Smadip1
is a member of the d-EF1/Zfh-1 family and harbors a
homeodomain-like sequence and a Smad-binding do-
main flanked by two clusters of zinc-finger sequences
that are both required for transcriptional repression of
receptor-activated Smad target genes (Remacle et al.
1999; fig. 4).
Mowat et al. (1998) were the first to point out the
clinical heterogeneity among patients with syndromic
HSCR with postnatal microcephaly and mental retarda-
tion (Mowat et al. 1998). They eventually identified a sub-
group of patients who shared characteristic dysmorphic
facial features, seizures, failure to thrive, and congenital
cardiac defect (Mowat et al. 1998). In one case, chro-
mosomal analysis revealed an interstitial deletion of
chromosome 2q21-q23. Most recently, SMADIP1 was
identified as the disease-causing gene in this syndrome
(Cacheux et al. 2001; Wakamatsu et al. 2001).
All mutant genotypes in our series were heterozygous
and were expected to produce a truncated or absent
Smadip1 protein. These data suggest that loss of function
(haploinsufficiency) at the SMADIP1 locus is the most
likely disease-causing mechanism. Moreover, since pa-
tients with SMADIP1 mutations have the same clinical
features as are observed in patients with large-scale de-
letions, the involvement of a contiguous gene(s) is un-
likely. Finally, all mutations reported here occurred de
novo, an observation that is in agreement with a very
severe phenotype in heterozygotes.
Comparison of the patients whom we studied with
those previously reported to harbor a SMADIP1mutation
allows further delineation of the clinical profile of this
novel syndromic HSCR entity. In particular, as frequent
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Figure 4 SMADIP1 gene structure. Top, Genomic structure. The SMADIP1 mutations identified are shown by downward-pointingarrows.
Bottom, SMADIP1 protein. The four N-terminal and three C-terminal zinc-finger domains (N-ZFD and C-ZFD, respectively), as well as the
Smad-binding domain (SBD), are indicated.
features in this syndrome, it is possible to include con-
genital defects of cardiac septation (in 62% of patients),
agenesis of the corpus callosum (in 50% of patients), and
hypospadias (table 4) (Lurie et al. 1994; Mowat et al.
1998; Wakamatsu et al. 2001). It is notable that all three
features result from defects in midline development. Re-
nal abnormalities (in three patients) and pyloric stenosis
(in two patients) are also notable. Conversely, the MCA-
MR (multiple-congenital-abnormalities–mental-retarda-
tion) syndrome, referred to as “Goldberg-Shprintzen syn-
drome” (MIM 235730), with HSCR, mental retardation,
and cleft palate is clearly a different condition, both on
the basis of clinical criteria and on the basis of mode of
inheritance (autosomal recessive). In the literature, three
patients reported to have had Goldberg-Shprintzen syn-
drome most likely presented with the syndromic HSCR
accounted for by SMADIP1mutations (Hurst et al. 1988,
case 3; Tanaka et al. 1993, patient S.179; Ohnuma et al.
1997). It would be interesting to either confirm or exclude
this hypothesis by studying SMADIP1 in families with
Goldberg-Shprintzen syndrome.
Whole-mount in situ hybridization in Xenopus showed
an early SMADIP1 expression in the dorsal ectoderm
and, later, in the dorsal neural tube and neural crests.
In addition, over-expression of SMADIP1 has led to an
enlargement of neural tissues and to ocular malforma-
tions (Eisaki et al. 2000). Thus, SMADIP1 could be
regarded as pleiotropic. Our data support these findings
and suggest that Smadip1 is involved not only in neural-
crest–derived cells (in the enteric nervous system and
craniofacial mesectoderm) and in the CNS but also in
heart septation (patent ductus arteriosus, as well as ven-
tricular and atrial septal defects) and development of mid-
line structures (corpus callosum and genitalia). There-
fore, although the putative involvement of SMADIP1 in
renal anomalies and in pyloric stenosis needs further
documentation, the expression pattern in human embryo
and the identification of SMADIP1 target genes should
be regarded as important.
Finally, the syndromic HSCR entity discussed in this
study (which, for clarity, we suggest should be named
after Lurie and Mowat) may be regarded as a recogniz-
able entity even in the absence of biopsy-proved HSCR,
as in one of the patients whom we studied (S.272). Thus,
this syndrome may be found to occur with greater fre-
quency than was originally expected, and we believe that
SMADIP1 mutations should be searched for in patients
with mental retardation, microcephaly, and agenesis of
the corpus callosum only. This hypothesis is currently
under investigation.
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